



CHARLOTTE'S WEB™
STANLEY BROTHERS



BRANDS – SCIENCE - LEADERSHIP

TSX: CWEB | OTCQX: CWBHF

Q2 2020

DISCLAIMERS

Forward-Looking Information

Certain statements contained in this presentation constitute forward-looking statements and forward-looking information (collectively, “forward-looking statements”). Such forward-looking statements relate to possible events, conditions or financial performance of Charlotte’s Web Holdings, Inc. (the “Company”) based on future economic conditions and courses of action. All statements other than statements of historical fact are forward-looking statements. The use of any words or phrases such as “seek”, “anticipate”, “plan”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “predict”, “potential”, “targeting”, “intend”, “could”, “might”, “should”, “believe”, “will likely result”, “are expected to”, “will continue”, “is anticipated”, “believes”, “estimated”, “intends”, “plans”, “projection”, “outlook” and similar expressions are intended to identify forward-looking statements. Examples of forward-looking statements include, among others, the Company’s assessment of, and targets for, sales of hemp-derived cannabidiol (“CBD”) products, expansion of retail locations through which the Company’s products may be sold, expansion of the Company’s distribution channels, including overseas distribution, development of improvements to the Company’s products and related bioavailability technology, the isolation of additional cannabinoid products, annual revenue, Adjusted EBITDA, and the Company’s outlook on expected regulatory developments regarding the 2018 Farm Bill, closing of the acquisition of Abacus Health Products, Inc. (“Abacus”), the impact of the acquisitions on the Company’s business and financial condition, anticipated product category growth, and online sales growth.

These statements involve known and unknown risks, assumptions, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking statements.

The forward-looking statements are based on management’s current opinions, estimates and assumptions in light of our experience and perception of historical trends, current trends, current conditions and expected future developments, as well as other factors that management currently believes appropriate and reasonable in the circumstances, including, among others, the adverse impact of the COVID-19 pandemic to the company’s operations, supply chain, distribution chain and to the broader market for and customers of the Company’s products; the impact of global conditions and unemployment rates on the Company’s stakeholders; general economic and financial conditions; product acceptance and competing products; internet and system infrastructure functionality; information technology security; cash available to fund operations; crop risk; availability of capital; completion of the acquisition of Abacus; the successful integration of acquired businesses; changes in customer demand; and the risk factors described in greater detail in the Company’s annual information form dated March 27, 2020, and other public documents of the Company available at www.sedar.com. The Company believes there is a reasonable basis for the expectations reflected in the forward-looking statements, however no assurance can be given that these expectations and the underlying opinions, estimates and assumptions will prove to be correct. The forward-looking statements included in this presentation should not be unduly relied upon by investors.

All of the forward-looking statements and information contained in this presentation speak only as of the date of this presentation and are expressly qualified by the foregoing cautionary statements. The Company expressly disclaims any obligation to update or alter statements containing any forward-looking statements, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by applicable law. Investors should read the Company’s public filings and consult their own professional advisors to ascertain and assess the income tax, legal, risk factors and other aspects of their investment in any securities of the Company.

Non-IFRS Measures and Industry Metrics

This presentation makes reference to Adjusted EBITDA (as defined below). Adjusted earnings before interest, taxes, depreciation and amortization (“Adjusted EBITDA”) is not a recognized performance measure under International Financial Reporting Standards (“IFRS”). Adjusted EBITDA does not have a standardized meaning prescribed by IFRS and may not be comparable to similar measures presented by other issuers. The term EBITDA consists of net (loss) income and excludes interest (financing costs), taxes, depreciation and amortization. Adjusted EBITDA also excludes share-based compensation, and share offering related costs, impairment of assets, and adjustments for fair value of both biological assets and warrant liabilities. Adjusted EBITDA is included as a supplemental disclosure because the Company believes that such measurement provides a better assessment of the Company’s operations on a continuing basis by eliminating certain non-cash charges and charges or gains that are nonrecurring. The most directly comparable measure to Adjusted EBITDA calculated in accordance with IFRS is net (loss) income. See “Adjusted EBITDA” in the Company’s most recently available management’s discussion and analysis of financial condition and results of operations available on the Company’s profile on SEDAR at www.sedar.com for a reconciliation of Adjusted EBITDA to net (loss) income.

Third Party Information

This presentation includes market and industry data which was obtained from various publicly available sources and other sources believed by the Company to be true. Although the Company believes it to be reliable, the Company has not independently verified any of the data from third-party sources referred to in this presentation or analyzed or verified the underlying reports relied upon or referred to by such sources, or ascertained the underlying assumptions relied upon by such sources. The Company does not make any representation as to the accuracy of such information.

Some numbers in this presentation may not be exact or add consistently due to rounding.



CHARLOTTE'S WEB WAS NOT STARTED
AS A COMPANY,

IT WAS STARTED AS A MISSION

Charlotte is our true north driving our passion and dedication to the best hemp extracts for product quality, safety and consistency.

What began as her story, became the shared story of hundreds of thousands, and the inspiration of many millions more in the journey of their betterment.

#1 BRAND IN THE TOTAL HEMP-DERIVED CBD MARKET ¹

OUTPACING PEERS WITH
2019 REVENUE GROWTH OF

36%
year-over-year²

- (1) By market share Company estimates
(2) Represents 2019 growth over 2018
(3) Charlotte's Web, Inc. revenue

CHARLOTTE'S WEB ANNUAL REVENUE (\$MM)



Quarterly Performance – Q1-2020


Q1- 2020 Financial Highlights

- Organic consolidated revenue of \$21.5
- 70% gross margin
- Adjusted EBITDA loss of \$5.7M
- \$53.0M cash, \$114.9M working cap

Q1- 2020 Business Highlights

- DTC sales increased 29% YoY, offsetting a 32% decrease in B2B sales
- 66% revenue from DTC
- Signed on first national pet retailer
- Nearly 12,000 retail doors
- J.P. Morgan engaged for commercial banking services and \$10 million line of credit (extendable to \$20M)

4-Yr Quarterly Revenue Growth (\$MM)



All revenue in USD \$MM

CHARLOTTE'S WEB
STANLEY BROTHERS



CHARLOTTE'S WEB ADVANTAGE

1. BRAND STRENGTH
2. VERTICALLY INTEGRATED SUPPLY CHAIN
3. INNOVATION, SCIENCE, SAFETY
4. MANAGEMENT TEAM

ADVANTAGE - BRAND STRENGTH

CHARLOTTE'S WEB IS #1 IN MARKET SHARE

AWARENESS

Charlotte's Web is #1 in awareness

Charlotte's Web is #1 in converting awareness to loyalty

SATISFACTION

Charlotte's Web is #1 in satisfaction


Charlotte's Web is #1 in intent to repurchase

Charlotte's Web is #1 in willingness to recommend

Ratings provided by respondents who have purchased the brand



ADVANTAGE - VERTICALLY INTEGRATED SUPPLY CHAIN



- Quality, consistency and trust
- Traceability of ingredient streams
- Transparency of the manufacturing process
- Grown in the U. S. A.
- Production Cost Advantages
- Over 50% crop acres certified organic with remainder transitioning



ADVANTAGE - INNOVATION



Original Portfolio



3 Gummies – **NEW 2019**



12 Canine Products – **NEW 2019**



ADVANTAGE - TESTED. CERTIFIED. SAFE.


All Products Tested up to 20 Times

- Testing through entire cultivation, extraction and manufacturing to final packaged product
- Includes 60-panel toxins test
- Batch test results available for every item sold

Certified

- FDA approved cGMP certified facilities
- NSF International's dietary supplements Good Manufacturing Practice (GMP) registration
- GRAS (generally recognized as safe) status for full spectrum hemp extract
- Hemp Authority certified products
- NASC certification for pet products

NAVIGATING A DYNAMIC CBD LANDSCAPE

- 
1. BALANCING REGULATORY FRAMEWORK DEVELOPMENT
 2. CW COMPETITIVE DIFFERENTIATION
 3. FOOD/DRUG/MASS CHANNEL DEVELOPMENT




EXPANDING THE PORTFOLIO ADVANTAGE

Topical Segment Underdeveloped

Segment	Charlotte's Web Portfolio Mix	Future Category Mix
Topicals	12%	30%
Tinctures	49%	25%
Capsules	11%	22%
Gummies	23%	8%
Pet	6%	14%

Expand Consumer Segment



ABACUS: ACQUISITION OF LEADING TOPICAL BRANDS



Consumer Offering

Health Care Practitioner Offering



ADVANCED RELIEF Powered by Nature™

OTC PEDIGREE



Proprietary Formulations

Patent-pending formulations based on 15+ years of R&D by Aidance Scientific (former parent)

Utilizing active pharmaceutical ingredients, natural ingredients, essential oils, and CBD hemp extract and oil (*Cannabis sativa L.*)


Manufacturing & Quality

OTC pharmaceutical-grade products

Produced in cGMP compliant facility by contract manufacturer

Production capacity of over 400,000 units/month - able to meet pent up demand

1 + 1 = 3 SCALE ACROSS CHANNELS



Scale and Synergy



EXPANDING CATEGORY LEADERSHIP

- 
1. LEVER PORTFOLIO DIFFERENTIATION
 2. SCALE ACROSS CHANNEL LEADERSHIP
 3. EXPAND LEADING ECOMMERCE OFFER
 4. LEAD WITH SCIENCE
 5. EXPAND & AUTOMATE DISTRIBUTION FOR SCALE

ADVANTAGE: PORTFOLIO DIFFERENTIATION

PORTFOLIO FOOTPRINT

Segments

- ✓ Ingestibles
- ✓ Topicals
- ✓ Bath & Beauty
- ✓ Pet

Channels

- ✓ FDM
- ✓ Natural
- ✓ Ecommerce
- ✓ Health Care Practitioners

CREDIBILITY



CBD CLINIC™

16K Health Care Practitioners



Education & Science

TECHNICAL ECOSYSTEM



ADVANTAGE: CHANNEL SCALE

Market Share Position - By Channel

<u>COMBINED SHARE*</u>		<u>INDEX VS NEXT COMPETITOR</u>
FOOD	#1	137
DRUG	#1	316
TOTAL FDM	#1	207
NATURAL	#2	79
eCOMMERCE	#1	N/A

Channel Distribution

<u>BRAND</u>	<u>CHANNEL DISTRIBUTION</u>			
	<u>FOOD</u>	<u>DRUG</u>	<u>NATURAL</u>	<u>eCOMM</u>
CHARLOTTE'S WEB	✓	✓	✓	✓
CBD MEDIC	UNDER CONSTRUCTION COMING SOON	✓	UNDER CONSTRUCTION COMING SOON	UNDER CONSTRUCTION COMING SOON
HARMONY HEMP	✓	✓	UNDER CONSTRUCTION COMING SOON	UNDER CONSTRUCTION COMING SOON



EXPANDING: eCOMMERCE CROSS-SELLING

EXPANDING CAPABILITIES

- Superior Analytics
- Breakthrough Insights
- Advantaged Segmentation
- Personalized Communication
- Rapid Test & Learn

IMPROVING KPI's

- Traffic
- Conversion
- Average Order Value
- Retention



July 2020: Cross-selling Abacus products to
30X active list on CW leading online store



ADVANTAGE: BUILD THE SCIENCE CREDENTIALS



Launched CW Labs - March 2020

- Co-located in the Hauptman Woodward Medical Research Institute in Buffalo, NY and Charlotte's Web labs in Boulder, CO
- Taps into the SUNY System – 64 Connected Campuses across New York
- Product development through scientific and clinical data-driven approach
- Comprehensive metabolite study on CW hemp extracts
- Human interventional placebo controlled clinical studies

Liver Safety Study



- **June 2020:** Sponsoring ValidCare human trial on impact of CBD on the liver to support FDA interest in science-based data

EXPANDING: SCALE & AUTOMATE

In-House Production

- New 137,000 sq ft cGMP grade manufacturing and R&D facility
- Extraction, production, distribution and R&D expansion
- CPG & Ecommerce shipping and distribution
- Staged build-out thru 2020 — Shipping end of Q2; Production end of Q3
- Capable of servicing the full F/D/M retail channel

Rigid Quality Management

- Leading CO₂ and alcohol extraction technologies
- Proprietary Extraction and Isolation Processes
- Current Good Manufacturing Practices (cGMP) Certifications





Deanie Elsner
CEO

- Kellogg's
- P&G
- Kraft
- Johnson & Johnson



Russ Hammer
CFO

- Caleres Brands
- ORBITZ INC
- CROCS INC
- MOTOROLA



David Panter
COO

- Estée Lauder
- Luxottica Retail
- Campbells
- Tyco Healthcare



Jared Stanley
CHIEF CULTIVATION
OFFICER

CHARLOTTE'S WEB
STANLEY BROTHERS



Tony True
CHIEF CUSTOMER
OFFICER

- PHARMAVITE
- WhiteWave
- Kellogg's, Pepsi, J&J



Perry Antelman
PRESIDENT, TOPICALS

- Abacus Health CEO
- Acquired June 2020

ADVANTAGE MANAGEMENT TEAM



Paul Lanham
DTC / CIO

- J.Jill
- CROCS
- Rally House



Kelly Shea
GOV'T RELATIONS,
COMMS, CSR

- Danone
- WhiteWave Foods
- Horizon Organic



Tim Orr
R&D INNOVATION

- Johnson & Johnson
- Abbott Laboratories
- Kodak Healthcare



Nathan Gerhardt
LEGAL/REGULATORY

- OMEGA PROTEIN
- NW Natural



Tamarah Saif
TALENT MGMT

- Green Chef
- Adecco Group



Cory Pala
CAPITAL MARKETS

- e-vestor
- TMX/Equicom

CHARLOTTE'S WEB
STANLEY BROTHERS



BALANCE SHEET & CAPITALIZATION

BALANCE SHEET	MARCH 31, 2020 <i>All figures shown in millions, US\$</i>
Cash	\$53.0
Working Capital	\$114.9
Total Assets	\$190.2
Total Liabilities	\$62.5
Shareholder Equity	\$127.7

CAPITALIZATION	June 22, 2020
Basic Common Shares Outstanding	101,787,521
Proportional Voting Shares (400:1)	92,455.5775 (400:1 = 36,982,230)
Effective Basic Common Shares Outstanding	138,769,751
Warrants	10,525,479
Options	4,890,678
Fully Diluted Shares Outstanding	154,185,908

SUMMARY

- MARKET SHARE LEADER
- EXPERIENCED CPG LEADERSHIP TEAM
- EVOLVING THE PORTFOLIO, INFRASTRUCTURE AND CAPABILITIES
- BACKED BY SCIENCE AND DATA
- BEST POSITIONED TO NAVIGATE THE OPERATING LANDSCAPE
- FULLY CAPITALIZED TO EXECUTE ON OUR STRATEGY

A close-up photograph of a pair of hands cupped together, holding a dark, rich soil. A small, vibrant green seedling with two leaves is growing out of the center of the soil. The background is dark and out of focus, emphasizing the hands and the plant.

TSX:CWEB | OTCQX:CWBHF

Charlotte's Web Holdings, Inc.

1600 Pearl Street

Boulder, Colorado

USA

www.charlottesweb.com

Cory Pala

Director of Investor Relations

(720) 484-8930

IR@CharlottesWeb.com